2024 ICD-10-CM Diagnosis Code T42.71

Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, accidental (unintentional)

ICD-10-CM Code:
T42.71
ICD-10 Code for:
Poisoning by unsp antieplptc and sed-hypntc drugs, acc
Is Billable?
Not Valid for Submission
Code Navigator:

Code Classification

  • Injury, poisoning and certain other consequences of external causes
    (S00–T88)
    • Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
      (T36-T50)
      • Poisoning by, adverse effect of and underdosing of antiepileptic, sedative- hypnotic and antiparkinsonism drugs
        (T42)

T42.71 is a non-specific and non-billable diagnosis code code, consider using a code with a higher level of specificity for a diagnosis of poisoning by unspecified antiepileptic and sedative-hypnotic drugs, accidental (unintentional). The code is not specific and is NOT valid for the year 2024 for the submission of HIPAA-covered transactions. Category or Header define the heading of a category of codes that may be further subdivided by the use of 4th, 5th, 6th or 7th characters.

Unspecified diagnosis codes like T42.71 are acceptable when clinical information is unknown or not available about a particular condition. Although a more specific code is preferable, unspecified codes should be used when such codes most accurately reflect what is known about a patient's condition. Specific diagnosis codes should not be used if not supported by the patient's medical record.

Specific Coding Applicable to Poisoning by unsp antieplptc and sed-hypntc drugs, acc

Non-specific codes like T42.71 require more digits to indicate the appropriate level of specificity. Consider using any of the following ICD-10-CM codes with a higher level of specificity when coding for poisoning by unsp antieplptc and sed-hypntc drugs, acc:

  • Use T42.71XA for initial encounter - BILLABLE CODE

  • Use T42.71XD for subsequent encounter - BILLABLE CODE

  • Use T42.71XS for sequela - BILLABLE CODE

Clinical Information

  • AIDS Arteritis, Central Nervous System

    inflammation of arteries in the central nervous system that occurs in patients with acquired immunodeficiency syndrome or aids-related opportunistic infections.
  • Brain Diseases

    pathologic conditions affecting the brain, which is composed of the intracranial components of the central nervous system. this includes (but is not limited to) the cerebral cortex; intracranial white matter; basal ganglia; thalamus; hypothalamus; brain stem; and cerebellum.
  • Brain Diseases, Metabolic

    acquired or inborn metabolic diseases that produce brain dysfunction or damage. these include primary (i.e., disorders intrinsic to the brain) and secondary (i.e., extracranial) metabolic conditions that adversely affect cerebral function.
  • Brain Diseases, Metabolic, Inborn

    brain disorders resulting from inborn metabolic errors, primarily from enzymatic defects which lead to substrate accumulation, product reduction, or increase in toxic metabolites through alternate pathways. the majority of these conditions are familial, however spontaneous mutation may also occur in utero.
  • Central Nervous System

    the main information-processing organs of the nervous system, consisting of the brain, spinal cord, and meninges.
  • Central Nervous System Agents

    a class of drugs producing both physiological and psychological effects through a variety of mechanisms. they can be divided into "specific" agents, e.g., affecting an identifiable molecular mechanism unique to target cells bearing receptors for that agent, and "nonspecific" agents, those producing effects on different target cells and acting by diverse molecular mechanisms. those with nonspecific mechanisms are generally further classed according to whether they produce behavioral depression or stimulation. those with specific mechanisms are classed by locus of action or specific therapeutic use. (from gilman ag, et al., goodman and gilman's the pharmacological basis of therapeutics, 8th ed, p252)
  • Central Nervous System Bacterial Infections

    bacterial infections of the brain, spinal cord, and meninges, including infections involving the perimeningeal spaces.
  • Central Nervous System Cysts

    congenital or acquired cysts of the brain, spinal cord, or meninges which may remain stable in size or undergo progressive enlargement.
  • Central Nervous System Depressants

    a very loosely defined group of drugs that tend to reduce the activity of the central nervous system. the major groups included here are ethyl alcohol, anesthetics, hypnotics and sedatives, narcotics, and tranquilizing agents (antipsychotics and antianxiety agents).
  • Central Nervous System Diseases

    diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.
  • Central Nervous System Fungal Infections

    mycoses of the brain, spinal cord, and meninges which may result in encephalitis; meningitis, fungal; myelitis; brain abscess; and epidural abscess. certain types of fungi may produce disease in immunologically normal hosts, while others are classified as opportunistic pathogens, causing illness primarily in immunocompromised individuals (e.g., acquired immunodeficiency syndrome).
  • Central Nervous System Helminthiasis

    infections of the brain; spinal cord; or meninges caused by helminths (parasitic worms).
  • Central Nervous System Infections

    pathogenic infections of the brain, spinal cord, and meninges. dna virus infections; rna virus infections; bacterial infections; mycoplasma infections; spirochaetales infections; fungal infections; protozoan infections; helminthiasis; and prion diseases may involve the central nervous system as a primary or secondary process.
  • Central Nervous System Neoplasms

    benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.
  • Central Nervous System Parasitic Infections

    infections of the brain, spinal cord, and meninges caused by parasites.
  • Central Nervous System Protozoal Infections

    infections of the brain, spinal cord, or meninges by single celled organisms of the former subkingdom known as protozoa. the central nervous system may be the primary or secondary site of protozoal infection. these diseases may occur as opportunistic infections or arise in immunocompetent hosts.
  • Central Nervous System Sensitization

    an increased response to stimulation that is mediated by amplification of signaling in the central nervous system (cns).
  • Central Nervous System Stimulants

    a loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. they work by a variety of mechanisms, but usually not by direct excitation of neurons. the many drugs that have such actions as side effects to their main therapeutic use are not included here.
  • Central Nervous System Vascular Malformations

    congenital, inherited, or acquired abnormalities involving arteries; veins; or venous sinuses in the brain; spinal cord; and meninges.
  • Central Nervous System Venous Angioma

    a vascular anomaly characterized by a radial or wedge-shaped arrangement of dilated veins draining into a larger vein in the brain, spinal cord, or the meninges. veins in a venous angioma are surrounded by normal nervous tissue, unlike a central nervous system cavernous hemangioma that lacks intervening nervous tissue. drainage of venous angioma is fully integrated with the body's venous system, therefore, in most cases there is no clinical signs and rare bleeding.
  • Central Nervous System Viral Diseases

    viral infections of the brain, spinal cord, meninges, or perimeningeal spaces.
  • Cerebral Phaeohyphomycosis

    cns infections caused by neurotropic dematiaceous fungi that contain melanin in their cell walls. the infections often result in brain abscess; encephalitis; and meningitis in patients who are often immunocompetent. the common causative fungi include members cladophialophora bantiana, exophiala dermatitidis, rhinocladiella mackenziei, and ochroconis gallopavum. r. mackenziei infection is seen almost exclusively in patients from the middle east.
  • Hemangioma, Cavernous, Central Nervous System

    a vascular anomaly composed of a collection of large, thin walled tortuous veins that can occur in any part of the central nervous system but lack intervening nervous tissue. familial occurrence is common and has been associated with a number of genes mapped to 7q, 7p and 3q. clinical features include seizures; headache; stroke; and progressive neurological deficit.
  • Hereditary Central Nervous System Demyelinating Diseases

    inherited conditions characterized by a loss of myelin in the central nervous system.
  • Lupus Vasculitis, Central Nervous System

    central nervous system vasculitis that is associated with systemic lupus erythematosus. clinical manifestations may include dementia; seizures; cranial nerve diseases; hemiparesis; blindness; dysphasia; and other neurological disorders.
  • Lyme Neuroborreliosis

    nervous system infections caused by tick-borne spirochetes of the borrelia burgdorferi group. the disease may affect elements of the central or peripheral nervous system in isolation or in combination. common clinical manifestations include a lymphocytic meningitis, cranial neuropathy (most often a facial neuropathy), polyradiculopathy, and a mild loss of memory and other cognitive functions. less often more extensive inflammation involving the central nervous system (encephalomyelitis) may occur. in the peripheral nervous system, b. burgdorferi infection is associated with mononeuritis multiplex and polyradiculoneuritis. (from j neurol sci 1998 jan 8;153(2):182-91)
  • Neurocysticercosis

    infection of the brain, spinal cord, or perimeningeal structures with the larval forms of the genus taenia (primarily t. solium in humans). lesions formed by the organism are referred to as cysticerci. the infection may be subacute or chronic, and the severity of symptoms depends on the severity of the host immune response and the location and number of lesions. seizures represent the most common clinical manifestation although focal neurologic deficits may occur. (from joynt, clinical neurology, 1998, ch27, pp46-50)
  • Neuroschistosomiasis

    schistosomiasis of the brain, spinal cord, or meninges caused by infections with trematodes of the genus schistosoma (primarily schistosoma japonicum; schistosoma mansoni; and schistosoma haematobium in humans). s. japonicum infections of the nervous system may cause an acute meningoencephalitis or a chronic encephalopathy. s. mansoni and s. haematobium nervous system infections are associated with acute transverse myelitis involving the lower portions of the spinal cord. (from joynt, clinical neurology, 1998, ch27, pp61-2)
  • Neurosyphilis

    infections of the central nervous system caused by treponema pallidum which present with a variety of clinical syndromes. the initial phase of infection usually causes a mild or asymptomatic meningeal reaction. the meningovascular form may present acutely as brain infarction. the infection may also remain subclinical for several years. late syndromes include general paresis; tabes dorsalis; meningeal syphilis; syphilitic optic atrophy; and spinal syphilis. general paresis is characterized by progressive dementia; dysarthria; tremor; myoclonus; seizures; and argyll-robertson pupils. (adams et al., principles of neurology, 6th ed, pp722-8)
  • Toxoplasmosis, Cerebral

    infections of the brain caused by the protozoan toxoplasma gondii that primarily arise in individuals with immunologic deficiency syndromes (see also aids-related opportunistic infections). the infection may involve the brain diffusely or form discrete abscesses. clinical manifestations include seizures, altered mentation, headache, focal neurologic deficits, and intracranial hypertension. (from joynt, clinical neurology, 1998, ch27, pp41-3)
  • Tuberculosis, Central Nervous System

    tuberculosis of the brain, spinal cord, or meninges (tuberculosis, meningeal), most often caused by mycobacterium tuberculosis and rarely by mycobacterium bovis. the infection may be limited to the nervous system or coexist in other organs (e.g., tuberculosis, pulmonary). the organism tends to seed the meninges causing a diffuse meningitis and leads to the formation of tuberculoma, which may occur within the brain, spinal cord, or perimeningeal spaces. tuberculous involvement of the vertebral column (tuberculosis, spinal) may result in nerve root or spinal cord compression. (from adams et al., principles of neurology, 6th ed, pp717-20)
  • Vasculitis, Central Nervous System

    inflammation of blood vessels within the central nervous system. primary vasculitis is usually caused by autoimmune or idiopathic factors, while secondary vasculitis is caused by existing disease process. clinical manifestations are highly variable but include headache; seizures; behavioral alterations; intracranial hemorrhages; transient ischemic attack; and brain infarction. (from adams et al., principles of neurology, 6th ed, pp856-61)
  • Vertigo

    an illusion of movement, either of the external world revolving around the individual or of the individual revolving in space. vertigo may be associated with disorders of the inner ear (ear, inner); vestibular nerve; brainstem; or cerebral cortex. lesions in the temporal lobe and parietal lobe may be associated with focal seizures that may feature vertigo as an ictal manifestation. (from adams et al., principles of neurology, 6th ed, pp300-1)

Coding Guidelines

When coding a poisoning or reaction to the improper use of a medication (e.g., overdose, wrong substance given or taken in error, wrong route of administration), first assign the appropriate code from categories T36-T50. The poisoning codes have an associated intent as their 5th or 6th character (accidental, intentional self-harm, assault and undetermined. If the intent of the poisoning is unknown or unspecified, code the intent as accidental intent. The undetermined intent is only for use if the documentation in the record specifies that the intent cannot be determined. Use additional code(s) for all manifestations of poisonings.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of antiepileptic, sedative- hypnotic and antiparkinsonism drugs (T42). Use the following options for the aplicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Tabular List of Diseases and Injuries

The following annotation back-references are applicable to this diagnosis code. The Tabular List of Diseases and Injuries is a list of ICD-10-CM codes, organized "head to toe" into chapters and sections with coding notes and guidance for inclusions, exclusions, descriptions and more.


Inclusion Terms

Inclusion Terms
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
  • Poisoning by antiepileptic and sedative-hypnotic drugs NOS

Table of Drugs and Chemicals

The code is referenced in the Table of Drugs and Chemicals, this table contains a classification of drugs, industrial solvents, corrosive gases, noxious plants, pesticides, and other toxic agents.

According to ICD-10-CM coding guidelines it is advised to do not code directly from the Table of Drugs and Chemicals, instead always refer back to the Tabular List when doing the initial coding. Each substance in the table is assigned a code according to the poisoning classification and external causes of adverse effects. It is important to use as many codes as necessary to specify all reported drugs, medicinal or chemical substances. If the same diagnosis code describes the causative agent for more than one adverse reaction, poisoning, toxic effect or underdosing, utilize the code only once.

Substance Poisoning
Accidental
(unintentional)
Poisoning
Accidental
(self-harm)
Poisoning
Assault
Poisoning
Undetermined
Adverse
effect
Underdosing
AnticonvulsantT42.71T42.72T42.73T42.74T42.75T42.76
Anticonvulsant
  »barbiturate
T42.71T42.72T42.73T42.74T42.75T42.76
Anticonvulsant
  »combination (with barbiturate)
T42.71T42.72T42.73T42.74T42.75T42.76
Anticonvulsant
  »hydantoin
T42.71T42.72T42.73T42.74T42.75T42.76
Anticonvulsant
  »hypnotic NEC
T42.71T42.72T42.73T42.74T42.75T42.76
Anticonvulsant
  »oxazolidinedione
T42.71T42.72T42.73T42.74T42.75T42.76
Anticonvulsant
  »pyrimidinedione
T42.71T42.72T42.73T42.74T42.75T42.76
Anticonvulsant
  »specified NEC
T42.71T42.72T42.73T42.74T42.75T42.76
Anticonvulsant
  »succinimide
T42.71T42.72T42.73T42.74T42.75T42.76
Antiepilepsy agentT42.71T42.72T42.73T42.74T42.75T42.76
Antiepilepsy agent
  »combination
T42.71T42.72T42.73T42.74T42.75T42.76
Antiepilepsy agent
  »mixed
T42.71T42.72T42.73T42.74T42.75T42.76
Antiepilepsy agent
  »specified, NEC
T42.71T42.72T42.73T42.74T42.75T42.76
Central nervous systemT42.71T42.72T42.73T42.74T42.75T42.76
Central nervous system
  »depressants
T42.71T42.72T42.73T42.74T42.75T42.76
Central nervous system
  »depressants
    »anesthetic (general) NEC
T42.71T42.72T42.73T42.74T42.75T42.76
Central nervous system
  »depressants
    »anesthetic (general) NEC
      »gases NEC
T42.71T42.72T42.73T42.74T42.75T42.76
Central nervous system
  »depressants
    »anesthetic (general) NEC
      »intravenous
T42.71T42.72T42.73T42.74T42.75T42.76
Central nervous system
  »depressants
    »barbiturates
T42.71T42.72T42.73T42.74T42.75T42.76
Central nervous system
  »depressants
    »benzodiazepines
T42.71T42.72T42.73T42.74T42.75T42.76
Central nervous system
  »depressants
    »bromides
T42.71T42.72T42.73T42.74T42.75T42.76
Central nervous system
  »depressants
    »cannabis sativa
T42.71T42.72T42.73T42.74T42.75T42.76
Central nervous system
  »depressants
    »chloral hydrate
T42.71T42.72T42.73T42.74T42.75T42.76
Central nervous system
  »depressants
    »ethanol
T42.71T42.72T42.73T42.74T42.75T42.76
Central nervous system
  »depressants
    »hallucinogenics
T42.71T42.72T42.73T42.74T42.75T42.76
Central nervous system
  »depressants
    »hypnotics
T42.71T42.72T42.73T42.74T42.75T42.76
Central nervous system
  »depressants
    »hypnotics
      »specified NEC
T42.71T42.72T42.73T42.74T42.75T42.76
Central nervous system
  »depressants
    »muscle relaxants
T42.71T42.72T42.73T42.74T42.75T42.76
Central nervous system
  »depressants
    »paraldehyde
T42.71T42.72T42.73T42.74T42.75T42.76
Central nervous system
  »depressants
    »sedatives; sedative-hypnotics
T42.71T42.72T42.73T42.74T42.75T42.76
Central nervous system
  »depressants
    »sedatives; sedative-hypnotics
      »mixed NEC
T42.71T42.72T42.73T42.74T42.75T42.76
Central nervous system
  »depressants
    »sedatives; sedative-hypnotics
      »specified NEC
T42.71T42.72T42.73T42.74T42.75T42.76
Central nervous system
  »muscle-tone depressants
T42.71T42.72T42.73T42.74T42.75T42.76
Central nervous system
  »stimulants
T42.71T42.72T42.73T42.74T42.75T42.76
Central nervous system
  »stimulants
    »amphetamines
T42.71T42.72T42.73T42.74T42.75T42.76
Central nervous system
  »stimulants
    »analeptics
T42.71T42.72T42.73T42.74T42.75T42.76
Central nervous system
  »stimulants
    »antidepressants
T42.71T42.72T42.73T42.74T42.75T42.76
Central nervous system
  »stimulants
    »opiate antagonists
T42.71T42.72T42.73T42.74T42.75T42.76
Central nervous system
  »stimulants
    »specified NEC
T42.71T42.72T42.73T42.74T42.75T42.76
HypnoticT42.71T42.72T42.73T42.74T42.75T42.76
Hypnotic
  »anticonvulsant
T42.71T42.72T42.73T42.74T42.75T42.76
Hypnotic
  »specified NEC
T42.71T42.72T42.73T42.74T42.75T42.76
Sedative NECT42.71T42.72T42.73T42.74T42.75T42.76
Sedative NEC
  »mixed NEC
T42.71T42.72T42.73T42.74T42.75T42.76
Sleeping draught, pillT42.71T42.72T42.73T42.74T42.75T42.76
SoporificT42.71T42.72T42.73T42.74T42.75T42.76
Soporific drugT42.71T42.72T42.73T42.74T42.75T42.76
Soporific drug
  »specified type NEC
T42.71T42.72T42.73T42.74T42.75T42.76

Patient Education


Medication Errors

Medicines treat infectious diseases, prevent problems from chronic diseases, and ease pain. But medicines can also cause harmful reactions if not used correctly. Errors can happen in the hospital, at the health care provider's office, at the pharmacy, or at home. You can help prevent errors by:

  • Knowing your medicines. When you get a prescription, ask the name of the medicine and check to make sure that the pharmacy gave you the right medicine. Make sure that you understand how often you should take the medicine and how long you should take it.
  • Keeping a list of medicines.
    • Write down all of the medicines that you are taking, including the names of your medicines, how much you take, and when you take them. Make sure to include any over-the-counter medicines, vitamins, supplements, and herbs that you take.
    • List the medicines that you are allergic to or that have caused you problems in the past.
    • Take this list with you every time you see a health care provider.
  • Reading medicine labels and following the directions. Don't just rely on your memory - read the medication label every time. Be especially careful when giving medicines to children.
  • Asking questions. If you don't know the answers to these questions, ask your health care provider or pharmacist:
    • Why am I taking this medicine?
    • What are the common side effects?
    • What should I do if I have side effects?
    • When should I stop this medicine?
    • Can I take this medicine with the other medicines and supplements on my list?
    • Do I need to avoid certain foods or alcohol while taking this medicine?

Food and Drug Administration


[Learn More in MedlinePlus]

Code History

  • FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
  • FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
  • FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.